{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:26:38Z","timestamp":1793607998469,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","award":["K08CA273542"],"award-info":[{"award-number":["K08CA273542"]}],"id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","award":["DE AC02-05CH11231"],"award-info":[{"award-number":["DE AC02-05CH11231"]}],"id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","award":["MCIN\/AEI\/10.13039\/501100011039"],"award-info":[{"award-number":["MCIN\/AEI\/10.13039\/501100011039"]}],"id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","award":["CSI144P20"],"award-info":[{"award-number":["CSI144P20"]}],"id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","award":["PID2020-118527RB-I00"],"award-info":[{"award-number":["PID2020-118527RB-I00"]}],"id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","award":["PID2023-153081OB-I00"],"award-info":[{"award-number":["PID2023-153081OB-I00"]}],"id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA184476"],"award-info":[{"award-number":["R01CA184476"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"US Office of Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["BC190820"],"award-info":[{"award-number":["BC190820"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005595","name":"University of California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.canlet.2026.218447","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T07:50:53Z","timestamp":1774338653000},"page":"218447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["AI-discovered cellular morphometric biomarkers in needle biopsy of prostate cancer predict neoadjuvant androgen deprivation therapy response and enable therapeutic targeting of mTOR in androgen deprivation therapy-resistant tumors"],"prefix":"10.1016","volume":"647","author":[{"given":"Hong","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4554-4808","authenticated-orcid":false,"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangbo","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6820-215X","authenticated-orcid":false,"given":"Manuel Jes\u00fas","family":"P\u00e9rez-Baena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7621-576X","authenticated-orcid":false,"given":"Alejandro","family":"Jim\u00e9nez-Navas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3706-8896","authenticated-orcid":false,"given":"Weidong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2400-624X","authenticated-orcid":false,"given":"Jesus","family":"P\u00e9rez-Losada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Yu","family":"Jen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5249-8434","authenticated-orcid":false,"given":"Sen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5994-9558","authenticated-orcid":false,"given":"Mary Helen","family":"Barcellos-Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9320-6021","authenticated-orcid":false,"given":"Jian-Hua","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth A.","family":"Iczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6793-9694","authenticated-orcid":false,"given":"Shuchi","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218447_bib1","first-page":"17","article-title":"Cancer statistics","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2026.218447_bib2","series-title":"Cancer Stat Facts: Prostate Cancer","author":"Institute","year":"2020"},{"key":"10.1016\/j.canlet.2026.218447_bib3","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.canlet.2026.218447_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.canlet.2026.218447_bib5","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1200\/JCO.18.01777","article-title":"Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone","volume":"37","author":"McKay","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218447_bib6","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41391-022-00496-8","article-title":"NEAR trial: a single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer","volume":"25","author":"Lee","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.canlet.2026.218447_bib7","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2022.09.009","article-title":"ARNEO: a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer","volume":"83","author":"Devos","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2026.218447_bib8","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1200\/JCO.2020.38.15_suppl.5504","article-title":"Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC)","volume":"38","author":"Efstathiou","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218447_bib9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1158\/1078-0432.CCR-20-2344","article-title":"Sequential prostate magnetic resonance imaging in newly diagnosed high-risk prostate cancer treated with neoadjuvant enzalutamide is predictive of therapeutic response","volume":"27","author":"Karzai","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218447_bib10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.eururo.2019.05.010","article-title":"Clinical and biological characterisation of localised high-risk prostate cancer: results of a randomised preoperative study of a luteinising hormone-releasing hormone agonist with or without abiraterone acetate plus prednisone","volume":"76","author":"Efstathiou","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2026.218447_bib11","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1158\/1078-0432.CCR-16-1357","article-title":"Neoadjuvant enzalutamide prior to prostatectomy","volume":"23","author":"Montgomery","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218447_bib12","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000002098.11","article-title":"PD61-11 a phase II study of 6-MONTHS apalutamide prior to radical prostatectomy in intermediate risk patients to reduce the frequency of pathologic features that drive post-operative radiation therapy","volume":"206","author":"Davis","year":"2021","journal-title":"J. Urol."},{"key":"10.1016\/j.canlet.2026.218447_bib13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/JU.0000000000001702","article-title":"Results of a randomized phase II trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer","volume":"206","author":"McKay","year":"2021","journal-title":"J. Urol."},{"key":"10.1016\/j.canlet.2026.218447_bib14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.clgc.2022.10.009","article-title":"Perioperative morbidity of radical prostatectomy after intensive neoadjuvant androgen blockade in men with high-risk prostate cancer: results of phase II trial compared to a control group","volume":"21","author":"Ilario","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.canlet.2026.218447_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2022.12.031","article-title":"Mapping european association of urology guideline practice across Europe: an audit of androgen deprivation therapy use before prostate cancer surgery in 6598 cases in 187 hospitals across 31 European countries","author":"MacLennan","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2026.218447_bib16","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2013.53.4578","article-title":"Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study","volume":"32","author":"Taplin","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218447_bib17","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1158\/1078-0432.CCR-16-1357","article-title":"Neoadjuvant enzalutamide prior to prostatectomy","volume":"23","author":"Montgomery","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218447_bib18","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1200\/JCO.18.01777","article-title":"Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone","volume":"37","author":"McKay","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218447_bib19","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1109\/TIP.2025.3579200","article-title":"RECIST(Surv): hybrid multi-task transformer for hepatocellular carcinoma response and survival evaluation","volume":"34","author":"Jiao","year":"2025","journal-title":"IEEE Trans. Image Process."},{"key":"10.1016\/j.canlet.2026.218447_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217438","article-title":"A foundation model with weak experiential guidance in detecting muscle invasive bladder cancer on MRI","volume":"611","author":"Gong","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218447_bib21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/neuonc\/noac154","article-title":"Clinical significance and molecular annotation of cellular morphometric subtypes in lower-grade gliomas discovered by machine learning","volume":"25","author":"Liu","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2026.218447_bib22","article-title":"AI-empowered cellular morphometric risk score improves prognostic stratification of cutaneous squamous cell carcinoma","author":"Perez-Baena","year":"2023","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.canlet.2026.218447_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1178568","article-title":"Pan-cancer evaluation of clinical value of mitotic network activity index (MNAI) and its predictive value for immunotherapy","volume":"13","author":"Mao","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218447_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115273","article-title":"Cellular morphometric biomarkers and large language model predict prognosis and treatment response in neuroblastoma patients: a retrospective and double-blind prospective single arm clinical study","author":"Wang","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218447_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.819565","article-title":"From mouse to human: cellular morphometric subtype learned from mouse mammary tumors provides prognostic value in human breast cancer","volume":"11","author":"Chang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218447_bib26","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.eururo.2021.03.009","article-title":"Nascent prostate cancer heterogeneity drives evolution and resistance to intense hormonal therapy","volume":"80","author":"Wilkinson","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2026.218447_bib27","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s10278-013-9622-7","article-title":"The cancer imaging archive (TCIA): maintaining and operating a public information repository","volume":"26","author":"Clark","year":"2013","journal-title":"J. Digit. Imag."},{"key":"10.1016\/j.canlet.2026.218447_bib28","unstructured":"A.C. Society, Prostate Cancer Risk Groups."},{"key":"10.1016\/j.canlet.2026.218447_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-022-00272-w","article-title":"Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance","volume":"6","author":"Ge","year":"2022","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.canlet.2026.218447_bib30","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/cncr.29927","article-title":"A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer","volume":"122","author":"Chow","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2026.218447_bib31","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1159\/000506625","article-title":"Exceptional response to everolimus in a patient with metastatic castrate-resistant prostate cancer harboring a PTEN inactivating mutation","volume":"13","author":"Kmak","year":"2020","journal-title":"Case Rep. Oncol."},{"key":"10.1016\/j.canlet.2026.218447_bib32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-019-0754-1","article-title":"Targeting mTOR for cancer therapy","volume":"12","author":"Hua","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218447_bib33","doi-asserted-by":"crossref","first-page":"7106","DOI":"10.1038\/onc.2008.318","article-title":"Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival","volume":"27","author":"Wang","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218447_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011088","article-title":"Role of PI3K-AKT-mTOR pathway as a pro-survival signaling and resistance-mediating mechanism to therapy of prostate cancer","volume":"22","author":"Pungsrinont","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218447_bib35","doi-asserted-by":"crossref","first-page":"LBA5002","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA5002","article-title":"A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: the MAST (metformin active surveillance trial) study","volume":"42","author":"Fleshner","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218447_bib36","doi-asserted-by":"crossref","first-page":"S1258","DOI":"10.1016\/j.annonc.2024.08.2313","article-title":"LBA70 adding metformin to androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC): overall survival (OS) results from the multi-arm, multi-stage randomised platform trial STAMPEDE","volume":"35","author":"Gillessen","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218447_bib37","unstructured":"G. Gebrael, C.H. Chehade, N. Agarwal, Metformin in prostate cancer, Lancet Oncol.."},{"key":"10.1016\/j.canlet.2026.218447_bib38","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1038\/s41598-018-38285-w","article-title":"The effect of metformin therapy on incidence and prognosis in prostate cancer: a systematic review and meta-analysis","volume":"9","author":"He","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218447_bib39","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218447_bib40","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician's choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218447_bib41","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218447_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.omto.2023.100755","article-title":"New advances in cancer therapy targeting TGF-\u03b2 signaling pathways","volume":"31","author":"Shou","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.canlet.2026.218447_bib43","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41392-020-00436-9","article-title":"Targeting TGF\u03b2 signal transduction for cancer therapy","volume":"6","author":"Liu","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218447_bib44","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1158\/1078-0432.CCR-21-3750","article-title":"Molecular pathways and mechanisms of TGF\u03b2 in cancer therapy","volume":"29","author":"Barcellos-Hoff","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218447_bib45","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1535-7163.MCT-20-0891","article-title":"Exploiting canonical TGF\u03b2 signaling in cancer treatment","volume":"21","author":"Liu","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2026.218447_bib46","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1158\/1078-0432.CCR-21-2846","article-title":"Validation of anticorrelated TGF\u03b2 signaling and alternative end-joining DNA repair signatures that predict response to genotoxic cancer therapy","volume":"28","author":"Guix","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218447_bib47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11263-014-0790-9","article-title":"Stacked predictive sparse decomposition for classification of histology sections","volume":"113","author":"Chang","year":"2015","journal-title":"Int. J. Comput. Vis."},{"key":"10.1016\/j.canlet.2026.218447_bib48","article-title":"Clinical significance and molecular annotation of cellular morphometric subtypes in lower grade gliomas discovered by machine learning","author":"Liu","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2026.218447_bib49","article-title":"From mouse to human: cellular morphometric subtype learned from mouse mammary tumors provides prognostic value in human breast cancer","volume":"11","author":"Chang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218447_bib50","doi-asserted-by":"crossref","first-page":"616","DOI":"10.5306\/wjco.v13.i7.616","article-title":"iCEMIGE: integration of CEll-morphometrics, MIcrobiome, and GEne biomarker signatures for risk stratification in breast cancers","volume":"13","author":"Mao","year":"2022","journal-title":"World J. Clin. Oncol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526002107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526002107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:34:32Z","timestamp":1793604872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526002107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":50,"alternative-id":["S0304383526002107"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218447","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AI-discovered cellular morphometric biomarkers in needle biopsy of prostate cancer predict neoadjuvant androgen deprivation therapy response and enable therapeutic targeting of mTOR in androgen deprivation therapy-resistant tumors","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218447","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218447"}}